{"slug":"ss-31-neuropathy","title":"SS-31 (Elamipretide) for Neuropathy: Mitochondrial Repair Evidence","body":"## What's breaking down\n\nNeuropathy often stems from mitochondrial dysfunction inside neurons. Damaged mitochondria leak reactive oxygen species, impair ATP production, and trigger cell death or poor signaling along nerves. This creates a repair deficit where breakdown outruns regeneration. Oxidative stress and inflammation compound the issue in many cases, whether from metabolic stress, injury, or genetic mitochondrial defects. The result is persistent nerve signaling problems rather than simple symptom masking.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial cardiolipin instability sits at the root of your nerve energy failure, SS-31 (Elamipretide) is discussed because it binds cardiolipin in the inner mitochondrial membrane. This stabilizes the membrane, supports electron transport chain efficiency, and lowers excess ROS production. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain. The logic chain runs: mitochondrial stabilization → better ATP output in neurons → reduced oxidative damage → support for nerve maintenance pathways.\n\n## How these fit together\n\nSingle-compound focus. SS-31 (Elamipretide) maps directly to the mitochondrial layer of degeneration. No sibling peptides in scope here.\n\n## What the evidence actually shows\n\nHuman data exist for one specific mitochondrial optic neuropathy. A phase II randomized, double-masked, vehicle-controlled trial tested topical elamipretide in 12 patients with Leber hereditary optic neuropathy (LHON, m.11778G>A mutation). The study ran 52 weeks double-masked followed by open-label extension. It assessed safety, tolerability, and potential efficacy on visual function (human tier). Preclinical mouse work showed clearer mitochondrial rescue: LPS-induced systemic inflammation caused hippocampal mitochondrial membrane potential drop, ATP loss, ROS rise, and memory deficits; SS-31 treatment reversed these markers, reduced apoptosis, preserved dendritic spines, and improved behavioral tests (preclinical tier). Rat spinal cord injury models have explored similar mitochondrial protection with behavioral readouts, but results vary across studies (preclinical tier). No large human trials address common peripheral neuropathy forms such as diabetic or idiopathic cases.\n\n## What scientists say\n\nResearchers note SS-31's selective cardiolipin interaction improves bioenergetics and curbs apoptosis in mitochondrial disease models. They highlight its blood-brain barrier penetration in some contexts and call for more human neuropathy-specific work beyond rare optic forms. LHON trial authors emphasize safety in humans while noting efficacy signals remain preliminary (mechanistic and human tiers).\n\n## What people say on Reddit\n\nAnecdotal reports from users with chronic fatigue or long COVID describe subjective energy gains and cognitive clarity after SS-31 use. One user reported regained toe sensation after years of numbness and attributed it to nerve-level repair (anecdotal tier). Others note no benefit or stress that the compound remains investigational. These accounts come from self-experimentation threads and lack controlled verification.\n\n## What people say on X\n\nLimited public discussion appears on X. Mentions stay general, focusing on mitochondrial support in aging or rare disease contexts rather than neuropathy anecdotes. No high-visibility verified user reports surface in recent searches.\n\n## What we do not know\n\nDirect human evidence for common peripheral neuropathies is absent. Long-term nerve regeneration outcomes remain untested in controlled settings. Dose-response relationships, optimal duration, and combination effects with other interventions lack published data. Whether benefits persist after stopping treatment is unknown.\n\n## Safety and limits\n\nHuman trials report good tolerability in mitochondrial disease populations, including Barth syndrome and primary mitochondrial myopathy studies (human tier). Topical LHON use showed acceptable local safety. Animal work flags no major acute toxicity at tested doses. Because human neuropathy data are sparse outside rare optic cases, any application stays exploratory. Regulatory status remains investigational for most indications.","register":"source_ledger","tags":["peptide","matrix"],"category":null,"style":{},"claims":[{"id":"c1","text":"SS-31 binds cardiolipin to stabilize inner mitochondrial membrane and reduce ROS.","section":"Why SS-31 (Elamipretide) might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Core proposed mechanism linking compound to mitochondrial repair in neurons."},{"id":"c2","text":"Phase II randomized trial of topical elamipretide in 12 LHON patients assessed safety and visual outcomes over 52 weeks.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Only human neuropathy-specific trial data available."},{"id":"c3","text":"In LPS mouse model, SS-31 reversed hippocampal mitochondrial dysfunction, lowered ROS and inflammation, preserved synapses, and improved memory tests.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Direct animal evidence of mitochondrial rescue in neuroinflammation model relevant to neuropathy."},{"id":"c4","text":"Reddit users with CFS/long COVID report subjective energy, cognitive, and one case of sensory nerve improvement after SS-31.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents real-world user claims separated from controlled data."},{"id":"c5","text":"No large human trials exist for common peripheral neuropathies such as diabetic neuropathy.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gap for typical reader conditions."}],"sources":[{"id":"s1","type":"review","url":"https://biomeme.com/applications/wellness/peptide-evidence/ss-31/","title":"SS-31 (Elamipretide) — Peptide Evidence Score","quote":"SS-31 selectively targets and stabilizes cardiolipin in the inner mitochondrial membrane... improves mitochondrial bioenergetics, reduces electron leak and ROS production","summary":"Mechanism summary from evidence framework page.","claim_ids":["c1"]},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37923251/","title":"Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial","quote":"This study aimed to assess the safety, tolerability, and potential efficacy of topical elamipretide in patients affected with Leber hereditary optic neuropathy (LHON).","summary":"Phase II human trial details for LHON.","claim_ids":["c2"]},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","title":"Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice","quote":"These findings indicate that LPS-induced memory impairment can be attenuated by the mitochondrion-targeted antioxidant elamipretide.","summary":"Mouse study abstract detailing mitochondrial and behavioral outcomes.","claim_ids":["c3"]},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/cfs/comments/1j2upcm/my_experience_treating_my_mecfs_with/","title":"My Experience Treating my ME/CFS with mitochondrial peptide SS-31","quote":"I can wiggle my toes in bed and feel them now. Ten years later! I 100% believe this is from the SS-31.","summary":"User anecdote on sensory recovery.","claim_ids":["c4"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}